Rezolute’s (RZLT) “Buy” Rating Reaffirmed at Guggenheim

Guggenheim reissued their buy rating on shares of Rezolute (NASDAQ:RZLT) in a research note published on Monday morning,Benzinga reports. They currently have a $15.00 target price on the stock.

Several other research analysts also recently commented on RZLT. BTIG Research restated a “buy” rating and issued a $17.00 target price on shares of Rezolute in a research note on Thursday, September 18th. Maxim Group raised their price target on Rezolute from $15.00 to $20.00 and gave the company a “buy” rating in a report on Thursday. HC Wainwright reissued a “buy” rating and set a $14.00 price objective on shares of Rezolute in a report on Wednesday, September 3rd. Finally, Wedbush reaffirmed an “outperform” rating and issued a $12.00 price target on shares of Rezolute in a research note on Thursday, September 18th. One investment analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $14.50.

Rezolute Stock Up 5.7%

NASDAQ RZLT opened at $8.14 on Monday. The business has a 50 day moving average price of $6.68 and a 200-day moving average price of $4.77. Rezolute has a 52 week low of $2.21 and a 52 week high of $8.81. The company has a market cap of $739.19 million, a price-to-earnings ratio of -8.39 and a beta of 0.02.

Rezolute (NASDAQ:RZLT) last announced its quarterly earnings results on Wednesday, September 17th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.03). On average, equities research analysts anticipate that Rezolute will post -0.93 earnings per share for the current year.

Institutional Trading of Rezolute

A number of hedge funds have recently bought and sold shares of RZLT. Ameriprise Financial Inc. bought a new stake in Rezolute during the fourth quarter valued at about $342,000. Man Group plc purchased a new stake in shares of Rezolute in the fourth quarter worth about $425,000. Jeppson Wealth Management LLC purchased a new stake in shares of Rezolute in the first quarter worth about $35,000. XTX Topco Ltd purchased a new stake in shares of Rezolute in the first quarter worth about $95,000. Finally, American Century Companies Inc. raised its position in Rezolute by 5.2% during the first quarter. American Century Companies Inc. now owns 67,925 shares of the company’s stock valued at $197,000 after purchasing an additional 3,334 shares during the period. Hedge funds and other institutional investors own 82.97% of the company’s stock.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.